Vanda Pharmaceuticals Inc. - Common Stock, par value $0.001 per share (VNDA)

Historical Holders from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
VNDA on Nasdaq
Shares outstanding
59,964,750
Price per share
$8.82
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
44,907,654
Total reported value
$224,087,389
% of total 13F portfolios
0%
Share change
-154,124
Value change
-$589,249
Number of holders
147
Price from insider filings
$8.82
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Vanda Pharmaceuticals Inc. - Common Stock, par value $0.001 per share (VNDA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 8.1% -47% $19,408,026 -$18,192,336 4,699,280 -48% BlackRock, Inc. 31 Jan 2025
BlackRock Portfolio Management LLC 7.7% $18,498,625 4,479,086 BlackRock Portfolio Management LLC 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 2.8% -50% $14,808,391 -$12,712,063 1,679,013 -46% Millennium Management LLC 31 Dec 2025
As of 30 Sep 2025, Vanda Pharmaceuticals Inc. - Common Stock, par value $0.001 per share (VNDA) has 147 institutional shareholders filing 13F forms. They hold 44,907,654 shares. of 59,964,750 outstanding shares (75%) .

Top 25 institutional shareholders own 64% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 15% 8,918,305 -5.5% 0% $44,502,342
VANGUARD GROUP INC 6% 3,587,139 +0.4% 0% $17,899,824
RENAISSANCE TECHNOLOGIES LLC 5.8% 3,476,925 +0.85% 0.02% $17,349,856
MILLENNIUM MANAGEMENT LLC 5.4% 3,250,836 +4.2% 0.01% $16,221,672
DIMENSIONAL FUND ADVISORS LP 4.3% 2,563,969 -0.84% 0% $12,793,562
TANG CAPITAL MANAGEMENT LLC 3.9% 2,353,307 0% 0.45% $11,743,002
ACADIAN ASSET MANAGEMENT LLC 3.7% 2,228,744 +29% 0.02% $11,115,000
GEODE CAPITAL MANAGEMENT, LLC 2.3% 1,392,085 -18% 0% $6,948,196
STATE STREET CORP 2.1% 1,271,079 +0.41% 0% $6,342,684
Krensavage Asset Management, LLC 2% 1,180,388 +15% 2.5% $5,890,000
TWO SIGMA ADVISERS, LP 1.5% 909,300 +12% 0.01% $4,537,407
Connor, Clark & Lunn Investment Management Ltd. 1.5% 904,544 +4.2% 0.01% $4,513,675
Empire Financial Management Company, LLC 1.3% 758,091 +289% 0.87% $3,782,874
FEDERATED HERMES, INC. 1.1% 681,836 -6.4% 0.01% $3,402,362
AQR CAPITAL MANAGEMENT LLC 1.1% 668,466 +393% 0% $3,335,646
TWO SIGMA INVESTMENTS, LP 1.1% 662,305 +26% 0.01% $3,304,902
MORGAN STANLEY 1.1% 637,499 -29% 0% $3,181,120
MARSHALL WACE, LLP 0.97% 581,247 +23% 0% $2,900,421
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.82% 488,936 +8.6% 0% $2,439,791
NORTHERN TRUST CORP 0.76% 454,572 -0.99% 0% $2,268,314
PRUDENTIAL FINANCIAL INC 0.75% 449,403 -26% 0% $2,242,521
GOLDMAN SACHS GROUP INC 0.57% 339,701 -16% 0% $1,695,108
GSA CAPITAL PARTNERS LLP 0.53% 318,799 -17% 0.13% $1,591,000
CITADEL ADVISORS LLC 0.44% 263,806 +78% 0% $1,316,392
Monaco Asset Management SAM 0.41% 247,805 -19% 0.46% $1,236,547

Institutional Holders of Vanda Pharmaceuticals Inc. - Common Stock, par value $0.001 per share (VNDA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 37,284 $312,373 -$765,269 $8.82 5
2025 Q3 44,907,654 $224,087,389 -$589,249 $4.99 147
2025 Q2 45,005,222 $212,432,729 +$5,358,378 $4.72 137
2025 Q1 43,925,314 $201,682,135 +$2,283,933 $4.59 145
2024 Q4 43,147,918 $206,663,597 -$5,282,442 $4.79 146
2024 Q3 43,866,766 $205,721,605 -$264,606 $4.69 150
2024 Q2 43,532,710 $245,988,498 -$19,571,791 $5.65 150
2024 Q1 47,945,494 $196,941,206 -$9,651,814 $4.11 138
2023 Q4 89,732 $378,669 -$292,766 $4.22 2
2023 Q3 52,472,384 $226,681,200 -$22,979,457 $4.32 177
2023 Q2 56,056,266 $369,430,051 -$15,079,006 $6.59 183
2023 Q1 58,238,552 $395,438,974 +$16,924,895 $6.79 174
2022 Q4 55,472,392 $409,940,964 +$13,786,425 $7.39 184
2022 Q3 41,739,419 $412,396,204 -$11,354,791 $9.88 162
2022 Q2 55,368,014 $602,478,252 -$3,401,631 $10.90 161
2022 Q1 55,863,449 $631,931,420 +$19,037,749 $11.31 177
2021 Q4 53,480,524 $839,068,026 -$31,785,679 $15.69 187
2021 Q3 55,220,766 $946,581,896 +$5,219,139 $17.14 174
2021 Q2 54,128,842 $1,163,953,080 -$3,361,111 $21.51 177
2021 Q1 54,065,958 $812,370,471 -$4,927,701 $15.02 180
2020 Q4 54,572,365 $717,253,120 +$6,496,248 $13.14 166
2020 Q3 53,981,049 $521,424,121 -$8,779,322 $9.66 154
2020 Q2 54,691,921 $625,606,920 +$15,790,144 $11.44 156
2020 Q1 53,478,283 $554,029,343 +$23,986 $10.36 149
2019 Q4 52,042,993 $853,971,538 -$1,863,298 $16.41 166
2019 Q3 52,122,145 $692,251,248 -$17,065,109 $13.28 156
2019 Q2 54,037,475 $761,461,143 +$14,205,671 $14.09 154
2019 Q1 54,037,386 $994,314,489 +$8,470,893 $18.40 173
2018 Q4 52,975,330 $1,383,751,451 +$26,879,081 $26.13 178
2018 Q3 52,178,300 $1,197,446,037 +$79,392,964 $22.95 155
2018 Q2 49,022,523 $933,879,055 +$18,597,011 $19.05 134
2018 Q1 48,202,587 $812,206,007 +$128,626,804 $16.85 131
2017 Q4 40,703,687 $618,707,889 +$12,359,119 $15.20 124
2017 Q3 39,671,132 $710,117,419 +$17,902,963 $17.90 136
2017 Q2 38,837,673 $633,047,808 -$6,210,327 $16.30 131
2017 Q1 39,458,719 $552,400,956 +$43,997,952 $14.00 134
2016 Q4 40,641,834 $648,298,745 -$10,122,917 $15.95 140
2016 Q3 38,916,956 $647,572,752 +$67,516,411 $16.64 136
2016 Q2 37,247,837 $416,814,941 -$42,220,620 $11.19 115
2016 Q1 41,259,486 $344,882,956 -$12,846,705 $8.36 115
2015 Q4 42,551,719 $396,336,229 -$31,254,001 $9.31 115
2015 Q3 42,710,087 $481,758,118 -$256,345 $11.28 120
2015 Q2 41,992,032 $532,719,965 -$34,781,330 $12.69 108
2015 Q1 46,203,365 $429,679,637 -$27,582,584 $9.30 107
2014 Q4 47,587,023 $680,931,306 +$76,430,299 $14.32 109
2014 Q3 41,268,115 $428,365,693 +$24,120,588 $10.38 101
2014 Q2 38,482,247 $622,313,434 +$52,888,902 $16.18 111
2014 Q1 35,159,995 $571,479,438 +$57,345,356 $16.25 109